BRUKER CORPORATION (NASDAQ:BRKR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On December 5, 2016, René Lenggenhager, President of the Bruker BioSpin Group, notified Bruker Corporation (the “Company”) that he will be leaving the Company, effective on or about February 24, 2017, in order to become the chief executive officer of COMET-Group AG, a publicly-traded Swiss company. Until such time, Dr. Lenggenhager will continue to serve as Bruker BioSpin Group President. The Company intends to initiate a search for a successor to Dr. Lenggenhager.
About BRUKER CORPORATION (NASDAQ:BRKR)
Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment. The Bruker BioSpin Group segment designs, manufactures and distributes enabling life science tools. The Bruker CALID segment designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as chemical, biological, radiological, nuclear and explosive (CBRNE) detection products. The Bruker Nano segment designs, manufactures and distributes spectroscopy and microscopy instruments. The BEST segment develops and manufactures superconducting and non-superconducting materials and devices. BRUKER CORPORATION (NASDAQ:BRKR) Recent Trading Information
BRUKER CORPORATION (NASDAQ:BRKR) closed its last trading session up +0.29 at 22.60 with 560,212 shares trading hands.
An ad to help with our costs